Exploration of IL6 as a surrogate for CKR Syndrome

About the Assay:

The Proxim IL6 assay was developed early 2018 due to cytokine release sybdrome (CRS) observed in the T-cell dependent bispecific (TDB) programs and the need for an assay with fast turnaround time. It is a Point of care assay that can be performed at the bedside and can measure IL6 within 15 minutes. It has a large dynamic range of 2-10,000pg/mL so there is also no need for sample dilution and handling.

What makes it unique:

The Proxim IL6 assay can provide immediate results on patient’s IL6 levels and enable clinicians to identify and potentially treat patients with CRS as well as Sepsis, both of which are life threatening conditions, earlier before manifestation of symptoms.